Cancer Type/Condition: Leukemia, acute lymphocytic (ALL), adult
Trial Type: Treatment
Trial Status: Active
1.
|
Phase: Phase IV Type: Treatment Status: Active Age: Over 55 Sponsor: Other Protocol IDs: GMALL02, NCT00198978
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: 15 to 65 Sponsor: Other Protocol IDs: GMALL01, NCT00198991
|
|
3.
|
Phase: Phase IV Type: Treatment Status: Active Age: Over 15 Sponsor: Other Protocol IDs: GMALL05, NCT00199082
|
|
4.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HEMOS ALL1105, NCT00797810
|
|
5.
|
Phase: Phase IV Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: LAL-AR/2003, NCT00853008
|
|
6.
|
Phase: Phase IV Type: Treatment Status: Active Age: 15 to 55 Sponsor: Other Protocol IDs: ALL-2009, NCT01193933
|
|
7.
|
Phase: Phase IV Type: Treatment Status: Active Age: 55 and over Sponsor: Other Protocol IDs: PETHEMA LAL-07FRAIL, NCT01358201
|
|
8.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: RJ-2010-56, NCT01358253
|
|
9.
|
Phase: Phase IV Type: Treatment Status: Active Age: 55 and over Sponsor: Other Protocol IDs: LAL-07OLD, NCT01366898
|
|
10.
|
Phase: Phase IV Type: Treatment Status: Active Age: 55 and under Sponsor: Other Protocol IDs: LAL Ph-2008, NCT01491763
|
|
11.
|
Phase: Phase IV Type: Treatment Status: Active Age: 16 to 65 Sponsor: Other Protocol IDs: HDE-ALL-2011, NCT01457040
|
|
12.
|
Phase: Phase IV Type: Treatment Status: Active Age: 15 to 60 Sponsor: Other Protocol IDs: LAL-AR/2011, NCT01540812
|
|
13.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 35 and under Sponsor: Other Protocol IDs: 2000LS040, MT2000-12, 0005M52481, UMN-2000LS040, NCT00176839
|
|
14.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: NILG-ALL 10/07, NCT00795756
|
|
15.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 1 to 50 Sponsor: Other Protocol IDs: HORCSCT-0902, NCT01015742
|
|
16.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 55 Sponsor: Pharmaceutical / Industry Protocol IDs: GRASPALL2009-06, NCT01518517
|
|
17.
|
Phase: Phase III Type: Treatment Status: Active Age: 25 to 65 Sponsor: Other Protocol IDs: JALSG ALL202-O, NCT00131027
|
|
18.
|
Phase: Phase III Type: Treatment Status: Active Age: 54 and under Sponsor: Other Protocol IDs: 0107M05202, MT2001-02, NCT00176930
|
|
19.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LMBA02, NCT00180882
|
|
20.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: 55/05, ALLG SC01, NHMRC Project Grant 331305, NCT00163722
|
|
21.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 59 Sponsor: Other Protocol IDs: GRAALL 2005, NCT00327678
|
|
22.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: ATGFamilyStudy, NCT00678275
|
|
23.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TK008, 2009-012973-37, NCT00914628
|
|
24.
|
Phase: Phase III Type: Treatment Status: Active Age: 16 to 30 Sponsor: Other Protocol IDs: PRODECYTE, NCT00944008
|
|
25.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 25 to 65 Sponsor: Other Protocol IDs: UCL-08-0167, UCL/08/0167, EU-21009, EUDRACT-2009-012717-22, UCL-UKALL14, MREC-09-H0711-90, NCRI-UCL-08-0167, CRUK-C27995-A9609, NCT01085617
|